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December 6, 2011:2544–9First, a prior study (4) had investigated the role of progressively
worsening glucose control in nondiabetic patients and its effects on
development of chronic kidney disease. With the well-established
role of chronic kidney disease, especially in dysglycemic patients
(5), it would be interesting to know if the investigators made any
attempts to look at the renal functions of the patients and made
any attempts to adjust for the same.
Second, it would also be interesting to know if the investigators
had data on levels of glycosylated hemoglobin (Hb) A1c for the
patients with IFG, and if any attempts were made to correlate the
same with events, as HbA1c has been indicated to better reflect
glycemic status even for IFG patients (6,7).
Third, it would be interesting to know the thoughts of the
investigators regarding the fact that addition of body mass index
only (Fig. 3, Model 3) (1), to the Model 2 (1) multivariable
analysis, changed the outcomes of the study from a statistically
significant one to one that is not.
The role of IFG in de novo cardiovascular events is a fascinating
topic, and we thank Dr. Yeboah and colleagues for shedding light
on interesting facets of the same.
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Reply
We thank Drs. Chatterjee and Maitra for their interest in our
paper regarding impaired fasting glucose and the risk of incident
diabetes mellitus and cardiovascular events in MESA (Multi-
Ethnic Study of Atherosclerosis) (1).
The first question raised was based on the paper by Fox et al. (2)
n glycemic control and development of kidney disease in the
ramingham Heart Study. Individuals with chronic kidney diseaseCKD) have an increased cardiovascular risk, but the relevance ofkidney function in statistical models depends on the cohort under
consideration and the question being asked. Covariates adjusted
for in our models were selected based on evidence of associations
in our univariate analysis and on prior publications. The MESA
cohort by design included relatively healthy individuals with a low
prevalence of CKD. Adding a measure of kidney disease (serum
creatinine, estimated glomerular filtration rate, or cystatin C levels)
did not change either the point estimates or the confidence
intervals of risk estimates reported in our paper.
The authors completely agree with regards to the second question
raised. Indeed, it would have been very interesting if data on
hemoglobin A1c were also provided. Unfortunately even though data
on hemoglobin A1c is available in MESA, it was measured during the
second MESA visit, whereas fasting blood glucose levels used in the
analysis to define participants as having normoglycemia, impaired
fasting glucose, or diabetes mellitus were measured during the
baseline examination (1). We believe that answering the same
question using samples from periods separated by years would yield
inaccurate results and would lead to inaccurate inferences.
Finally, the addition of body mass index to the stepwise Cox
proportional hazard model that included age, sex, and race/ethnicity
attenuated the univariate association between impaired fasting glucose
and incident cardiovascular events in MESA. This is not surprising
given the strong association between body mass index and glucose.
Thus, the apparent association between impaired fasting glucose and
incident cardiovascular events in our univariate analysis could be
explained by a combination of the variance in age, sex, race/ethnicity,
and the body mass index of the subcohort.
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Determinants of Exercise
Intolerance in Heart Failure
With Preserved Ejection Fraction
The article by Haykowsky et al. (1) is a comprehensive examina-
tion of contributors to the reduced exercise capacity universally
